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Abstract
Background: Effects of nitric oxide (NO) on hemostasis have been studied in various investigational settings, but
data regarding inhaled NO on bleeding and platelet function are conflicting. It is not known if inhaled NO has an
effect when administered with drugs that influence hemostasis. This trial evaluated effects of inhaled NO on
hemostasis in the presence of heparin using aspirin as a positive control.
Patients/Methods: Twelve healthy adult males were enrolled in a single-center, randomized, single-blind, four-way
crossover trial. Subjects received 80 ppm NO or medical air (placebo) inhalation for 30 min with simultaneous
injection of placebo or heparin. Aspirin capsules were used as a positive control. Parameters of hemostasis were
measured before treatment and at post-treatment intervals.
Results: Activated clotting time (ACT), prothrombin time (PT) and activated partial thromboplastin time (aPTT)
increased only in groups that received heparin. Areas under the curve for ACT in heparin groups receiving inhaled
NO were judged to be equivalent to those receiving medical air for both 0- to 4-h (ratio: 1.00; 90% CI, 0.90-1.11)
and 0- to 24-h time intervals (ratio: 1.01; 90% CI, 0.92-1.12). Changes in bleeding time and platelet aggregation
were observed only in aspirin groups. No clinically significant changes in hemoglobin, red blood cell counts or
haematocrit were observed in any group.
Conclusions: Inhaled NO, when administered with heparin, exhibited no significant additive effects on ACT, PT,
aPTT, bleeding time or platelet aggregation.
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Introduction
Nitric oxide (NO) is produced endogenously and plays
an important role in a range of physiologic functions
including the regulation of vascular smooth muscle
tone, as well as the modulation of platelet function via
the guanylate cyclase signaling pathway [1]. Inhaled NO
is approved for the treatment of term and near-term (>
34 weeks) neonates with hypoxic respiratory failure
associated with clinical or echocardiographic evidence of
pulmonary hypertension, where it selectively relaxes the
pulmonary vasculature, reduces right to left shunting of
poorly oxygenated blood, and thereby improves oxyge-
nation [2-4]. The vasodilatory effects of inhaled NO are
localized to the pulmonary vasculature because NO is
immediately converted to nitrite and methemoglobin
[5]. However, there are potential but as yet hypothetical
systemic effects of inhaled NO, including possible per-
ipheral effects on platelet function and bleeding, that
have prompted a variety of studies.
Early studies in healthy human volunteers and animals
demonstrated prolonged bleeding times following inha-
lation of NO [6,7]. While some later studies were confir-
matory of these findings [8-10], others found no effect
on bleeding time [11,12] or found an increase in bleed-
ing time only after prolonged (e.g. 55 min) exposure to
inhaled NO [13]. Studies of the effects of inhaled NO
on bleeding in adults and neonates with respiratory
complications have been similarly conflicting. Some
investigators reported increased bleeding time [14,15],
whereas others reported no increase in bleeding time or* Correspondence: brahm.goldstein@ikaria.com
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the incidence of clinically significant hemorrhage
[16-18].
With regard to platelet aggregation, the effects of
inhaled NO have been investigated in animals, healthy
adults, and neonates. Again, this diverse group of studies
has yielded conflicting results. Some investigators have
reported inhibition of platelet function or aggregation
[10,14,18-24], while others have found little or no effect
[8,11-13,15,25].
While studies examining the effects of inhaled NO on
bleeding and platelet function have yielded inconsistent
results, it is also not known if inhaled NO has an addi-
tive or synergistic effect when given in combination
with other drugs that influence hemostasis. The clinical
implications of the potential adverse effects of inhaled
NO on hemostasis may be significant in surgical settings
where anticoagulants may be employed and in neonates
who are placed on anticoagulation therapy for extracor-
poreal membrane oxygenation. In both circumstances,
patients may have received inhaled NO before, during,
or after anticoagulation therapy. To address these issues,
this study was designed to evaluate effects of inhaled
NO on coagulation and platelet aggregation in the pre-
sence and absence of heparin, with aspirin as a positive
control.
Methods
Patients and study design
This was a single-center, randomized, single-blind, four-
way crossover study conducted at Inveresk Clinical
Research (ICR), Edinburgh, Scotland. The study was
approved by the Independent Ethics Review Committee
of Inveresk Research and all subjects gave written
informed consent. The study was conducted in accor-
dance with Guidance on Good Clinical Research Prac-
tice in the European Community and the International
Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human
Use. Quality control and quality assurance were carried
out by ICR.
The study was initiated in November 1998 and was
completed in December 1998. Healthy, non-smoking
males aged 18 to 50 years were considered eligible for
inclusion. The use of any investigational drugs (≤4
months prior to study entry), the need for prescription
or over-the-counter drugs (≤7 days prior to study entry),
a history or suspicion of bleeding disorders, recent sur-
gery or significant trauma (≤3 months prior to screen-
ing) and blood donation or loss (> 400 ml; ≤12 weeks
prior to study entry) were among the exclusion criteria
(Table 1).
Four treatment combinations were employed as fol-
lows:
1. Heparin injection + placebo inhalation + placebo
capsules (HPP).
2. Placebo injection + NO inhalation + placebo cap-
sules (PNP).
3. Heparin injection + NO inhalation + placebo cap-
sules (HNP).
4. Placebo injection + placebo inhalation + aspirin
capsules (PPA).
The study was conducted in four successive treatment
periods, with patients randomly assigned to receive a
different treatment combination during each treatment
period. Randomization was performed via computer-
generated, 4-digit sequences, corresponding to the treat-
ment combinations listed above. Randomization codes
were held by the study pharmacist, who was the sole
preparer of dosing and kept randomization blinded to
all members of the study team.
There was a 7- to14-day washout period between treat-
ments. The primary end point was activated clotting time
(ACT), determined via area under the curve (AUC) for the
HPP and HNP treatment combinations over a period of
24 h (AUC0®24). This measure was chosen as the primary
end point based on its use in monitoring heparin anticoa-
gulation at the time of study; given that the intent of the
study was to provide insight as to the impact of concomi-
tant use of inhaled NO and heparin on hemostasis, the
choice of ACT was deemed to be appropriate.
Secondary analyses included AUC measurements of
ACT for the PNP and PPA combinations over the first
four hours (AUC0®4), as well as pharmacodynamic
parameters that included activated partial thromboplas-
tin time (aPTT), prothrombin time (PTT), bleeding
time, creatinine clearance, and methemoglobin levels.
Injections were given as 5 ml of either heparin (5,000 i.
u.) or 0.9% sodium chloride (placebo), administered as an
intravenous bolus injection. Capsules were administered
orally as 2 × 300 mg aspirin or matching placebo (lac-
tose) with 200 ml of water, 15 min prior to the simulta-
neous administration of injections and inhalations. The
doses of both heparin and aspirin were based on recom-
mended doses to be used in clinical situations at the time
of the study. Gas inhalations were either 80 ppm NO or
medical air (placebo) administered for 30 ± 1 min by an
lNOvent® delivery system (Datex-Ohmeda, Inc.; Madi-
son, WI) with an inspired air flow of 8 ± 2 L/min. The
doses of inhaled NO and aspirin were based on previous
studies of this type in healthy volunteers [11,13].
Nitrogen-based Gas Measurements
Nitric oxide and nitrogen dioxide (NO2) were measured
by the INOvent® delivery system at 5, 10, 15, and 30
min after commencement of gas delivery.
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Laboratory tests
Serial blood samples were collected via cannula placed
in subjects’ forearms, which were flushed with saline;
approximately 175 mL of blood was obtained from
each subject over the duration of the study. Samples
for clinical chemistry and hematology were collected
in heparinized tubes (5.0 ml), EDTA-coated tubes (3.0
ml) and in citrated anticoagulant tubes (2.7 ml).
Hemoglobin (Hb), total red blood cell (RBC) count
and hematocrit (Hct) were performed with a Techni-
con H1 Analyser (Bayer/Technicon Instruments; Tar-
rytown, NY). Tests were performed immediately
before and 24 h after commencement of each treat-
ment period, and 7 days after the final treatment
period.
ACT, aPTT, PT, and Heparin Concentration
Standard analyses for ACT (Hattersley method [26];
kaolin activator), aPTT (Larrieu and Weiland method
[27]), and PT (Biggs and Macfarlane method [28]) assays
were performed immediately before dosing and at inter-
vals following commencement of gas inhalation (5 min,
10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h [excluding
ACT], and 24 h [± 2 h]).
Heparin concentration was determined based on anti-
factor Xa activity using a chromogenic substrate assay.
Bleeding Times
Bleeding times were measured using the modified Ivy
Nelson method immediately prior to dosing and at 10
min, 30 min, 1 h, 2 h, 4 h, and 12 h after commence-
ment of gas inhalation.
Platelet Aggregation
Platelet aggregation was induced by collagen (2 μg/ml)
or adenosine diphosphate (ADP) (10 μM), and measure-
ments were executed by Born light aggregometry. Ago-
nist-induced aggregation was quantified via
measurement of maximal light transmission (measured
as a percentage). Venous blood samples (10 ml) were
taken immediately prior to dosing and 30 min, 1 h and
24 h following commencement of gas inhalation.
Methemoglobin
Methemoglobin concentrations in venous blood were
measured immediately prior to dosing and 30 min, 1 h
and 2 h following commencement of gas inhalation with
an IL-682™ CO-oximeter (Instrumentation Laboratory,
Brussels, Belgium).
Cyclic GMP
Plasma cyclic guanosine monophosphate (cGMP) levels
were measured in samples taken at -5, -10, +5, +45 and
Table 1 Study Exclusion Criteria
Exclusion Criteria
Administration of any investigational drug in the period 0 to 3 months before entry to the study (0 to 4 months if the previous investigational drug
was a new chemical entity)
A need for any medication (including OTC drugs, e.g., aspirin) during the period 0 to 7 days before entry to the study
Existence of any surgical or medical condition which, in the judgment of the clinical investigator, might interfere with the absorption, distribution,
metabolism or excretion of the drug
Presence or history of allergy requiring treatment
Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before entry to the study
Serious adverse reaction or hypersensitivity to any drug, especially heparin
History of easy bruising
Personal or family history or coagulation or bleeding disorders, cerebral hemorrhage, or reasonable suspicion or vascular malformations, including
aneurysms
History of important bleeding, e.g., hematemesis or melena, severe or recurrent epistaxis or hemoptysis
Known heparin resistance
Consumption of aspirin in any form, or of other non-steroidal anti-inflammatory drugs within the 3 weeks prior to the final eligibility check
Rectal bleeding, including that presumed from hemorrhoids within 3 months prior to screening
Surgery or significant trauma within the 3 months prior to screening
Significant epigastric pain or indigestion either chronically or within 4 weeks prior to screening
Platelet aggregation response of 40% to 10 μmol/L ADP and 2 μg/mL collagen
Abnormal platelet aggregation response to arachidonic acid
Inability to communicate or co-operate with the investigator because of a language problem, poor mental development or impaired cerebral
function
Smokers
Objection by the subject’s general practitioner to his/her patient’s participation in the study
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+60 min relative to commencement of inhalation. Blood
was collected into chilled heparinized tubes, placed on ice,
then centrifuged at 2500 rpm for 5 min. Plasma was then
separated, with 1.5 mL placed in a polypropylene tube and
the remainder in a second tube. Samples were stored at
-70°C and then assayed at the Department of Clinical
Pharmacology at Lund University in Sweden. Estimations
for cGMP were assayed in a subgroup of 6 subjects (dur-
ing Treatment Period 3 only) as a marker of biological
activity and were not considered pivotal study data.
Statistical analysis and sample size determination
Summary statistics (i.e. arithmetic mean, median, stan-
dard deviation, minimum, maximum and n) were calcu-
lated for all treatment combinations and all
measurements. The primary analysis end point was
defined to be the activated clotting time (ACT). A curve
representing ACT versus time was produced, and AUC
0®4 and AUC 0®24 was calculated for each subject and
dosing session. Following logarithmic transformation,
the AUC values were subjected to analysis of variance,
including terms for subject, period and treatment com-
bination. For the primary analysis, a point estimate and
90% confidence interval for the difference between the
HNP and HPP combinations were constructed. If the
90% confidence interval for the measure of relative
“bioavailability” (i.e. AUC ratio of the HNP combination
relative to the HPP combination) lay within the accep-
tance range of 0.80 to 1.25, the two combinations of
interest were judged equivalent. For the secondary end
point, HNP was also compared with PNP and PPA
using similar methods.
Sample size determination
In a previous, unpublished study in healthy volunteers
(Data on file; Ikaria, Inc., Clinton, NJ), the mean ACT
value after heparinization was 269 s, with an associated
between-subject standard deviation of 27.5 s. Assuming
a correlation coefficient of 0 between ACT values from
two treatment periods in the same subject, the standard
deviation associated with the difference is 38.9 s. A total
of seven subjects was required in order to have a rea-
sonable chance (i.e. power 90%) that the 90% confidence
interval of the measure of relative bioavailability (i.e.
AUC ratio) would lie within the acceptance range of
0.80 to 1.25, assuming that the two combinations of
interest are equivalent. Based on considerations of dif-
ferences between the previous study and this study, a
sample size of 12 was recommended.
Results
Patients and Demographics
Twelve subjects entered the study, with one subject
withdrawing after receiving the HPP combination in the
first treatment session. All subjects were healthy white
males with a mean age of 33.6 years ± 11.9 SD, mean
height of 179.1 cm ± 6.2 SD, and mean weight of 80.2
kg ± 11.7 SD (Table 2).
Primary end point - ACT
Over the first 4 h, ACT was higher in groups that
received heparin injection (HPP and HNP groups) than
in groups that received placebo injection (PNP or PPA),
but all four treatment combinations appeared similar
from 4 to 24 h post-treatment (Figure 1). AUC analysis
was performed for ACT vs. time for data collected from
0-4 h post-treatment and for 0-24 h post-treatment.
Results are summarized in Table 3. For the 0- to 4-h
interval, the ratio of the AUCs of the HNP combination
relative to the HPP combination was 1.00 with a 90%
confidence interval of 0.90 to 1.11, within the accep-
tance range of 0.80 to 1.25 (Table 3). Consequently, the
two combinations were judged equivalent, and the addi-
tion of inhaled NO did not change ACT when given
together with a heparin injection. The HNP and HPP
combinations were also judged to be equivalent for the
0-24 h interval. The AUC values for the HNP combina-
tion were, on average, 76% higher than the PNP combi-
nation for the 0- to 4-h interval and indicated that the
addition of heparin increased ACT (Table 3). Similarly,
the AUC values for the HNP combination over the first
4 h were, on average, 79% higher than the PPA combi-
nation, indicating that adding a heparin injection
increased ACT as compared with aspirin (Table 3).
However, these differences were less for the 0- to 24-h
interval.
Table 2 Patient Demographics
Patient* Treatment Sequence Age Height (cm) Weight (kg)
001 HPP/PNP/PPA/HNP 34 181 77.9
002 HNP/PPA/PNP/HPP 28 170 74.4
003 PNP/HNP/HPP/PPA 46 181 93.9
004 PPA/HPP/HNP/PNP 23 179 64.7
005 HPP/PNP/PPA/HNP 49 179 84.3
006 PNP/HNP/HPP/PPA 47 176 82.5
007 PPA/HPP/HNP/PNP 26 181 88.4
008 HNP/PPA/PNP/HPP 41 193 104.3
009 HNP/PPA/PNP/HPP 48 175 70.9
010 HPP/PNP/PPA/HNP 20 180 69.7
011 PNP/HNP/HPP/PPA 19 170 67.7
012 PPA/HPP/HNP/PNP 22 184 84.1
*All patients were white males.
HNP, heparin injection + nitric oxide inhalation + placebo capsules; HPP,
heparin injection + placebo inhalation + placebo capsules; PNP, placebo
injection + nitric oxide inhalation + placebo capsules; PPA, placebo injection +
placebo inhalation + aspirin capsules.
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Adverse events and safety
No serious adverse events (AEs) were reported. The
only AE reported was that of vomiting, which occurred
in a patient who received the PNP combination.
PT and aPTT
The mean results for PT and aPTT showed an increase
after injection only in the groups that received heparin
(HPP and HNP), with values returning to near baseline
by 4 h (Figure 2).
Heparin Concentration
Increased anti-factor Xa activity was measured from 5
min to 2 h post-treatment in the groups that received
heparin injection (Figure 3), and there was no evidence
of anti-factor Xa activity in the groups that received pla-
cebo injection. In addition, there was no evidence of
additional potentiation of anticoagulant effects when
heparin and NO were administered simultaneously.
Bleeding Time
Extended bleeding times were noted from 10 min to 2 h
post-dose for the group treated with aspirin (PPA
group) (Figure 4), but not in any of the other groups. In
general, changes were mild, and few values fell outside
normal limits. Data from the other treatment groups (i.
e. HPP, PNP and HNP) were within expected limits
throughout the study.
Platelet Aggregation
Effects on platelet aggregation were restricted to the
group treated with aspirin (PPA) (Figure 5). Response to
ADP was generally unaffected, with no changes in plate-
let aggregation in the HPP, PNP, and HNP groups (Fig-
ure 5A). Individual responses to a single dose were
variable, but several subjects experienced inhibition of
collagen-induced platelet aggregation (Figure 5B), typical
for the pharmacologic action of aspirin.
Cyclic GMP
As mentioned previously, 6 patients had cGMP estima-
tions conducted during Treatment Period 3 (Figure 6);
these measurements were performed as a marker of bio-
logical activity and were considered non-pivotal data.
Among the 6 patients, 4 had cGMP levels that remained
Figure 1 ACT before and at various time points after treatment with inhaled nitric oxide or placebo gas. Data points represent mean ±
SD. ACT, activated clotting time; HNP, heparin injection + nitric oxide inhalation + placebo capsules; HPP, heparin injection + placebo inhalation
+ placebo capsules; PNP, placebo injection + nitric oxide inhalation + placebo capsules; PPA, placebo injection + placebo inhalation + aspirin
capsules.
Table 3 Area Under the Curve for Activated Clotting
Time
0-4 h 0-24 h
Means* Comparison Means* Comparison
Treatment (s·h) Ratio† (90% CI) (s·h) Ratio† (90% CI)
HPP 526.75 1.00 (0.90, 1.11) 2,181.53 1.01 (0.92, 1.12)
PNP 297.70 1.76 (1.58, 1.96) 1,934.88 1.14 (1.03, 1.26)
HNP 524.43 - 2,206.74 -
PPA 292.55 1.79 (1.61, 1.99) 1,922.91 1.15 (1.04, 1.27)
CI, confidence interval; HPP, heparin injection + placebo inhalation + placebo
capsules; HNP, heparin injection + NO inhalation + placebo capsules; NO,
nitric oxide; PNP, placebo injection + NO inhalation + placebo capsules; PPA,
placebo injection + placebo inhalation + aspirin capsules.
*Geometric means from analysis of variance.
†Ratio defined as HNP divided by relevant other combination (after
exponential transformation of difference on logarithmic scale).
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relatively stable. Two patients (PNP and HNP) had
cGMP elevations that peaked at 5 and 15 min, respec-
tively, and then returned to near-baseline levels by the
end of the treatment period (min 45-60).
Hematology
Hemoglobin, RBC and Hct levels were assessed immedi-
ately prior to study dose and 24 h post-dose. No clini-
cally significant changes from baseline were found for
mean values for any of the study combinations. In some
subjects, there was a decrease in Hb and Hct as the
study progressed, but this was presumed to be due to
repeated venesection.
Creatinine
Increases from baseline mean plasma creatinine were
observed in the HPP (+13.0 ± 14.3 μmol/L), PNP
(+15.9 ± 12.3), HNP (+17.0 ± 14.0), and PPA (+8.9 ±
12.5) groups at hour 12. By hour 24, no substantial
changes from baseline in creatinine levels were noted
(+4.0 ± 4.7, +7.2 ± 5.7, +3.8 ± 5.4 and +4.9 ± 5.3,
respectively). Nine patients (2 in the HPP, HNP and
PPA groups and 3 patients in the PNP group) exhib-
ited above-normal creatinine levels (upper limit of nor-
mal: 122 μmol/L) at hour 12. Two patients (one in
HPP and one in PNP) had above-normal creatinine
levels at 24 h.
Figure 2 (A) PT and (B) aPTT before and at various time points after treatment with inhaled nitric oxide or controls. Data points
represent mean ± SD. aPTT, activated partial thromboplastin time; HNP, heparin injection + nitric oxide inhalation + placebo capsules; HPP,
heparin injection + placebo inhalation + placebo capsules; PNP, placebo injection + nitric oxide inhalation + placebo capsules; PPA, placebo
injection + placebo inhalation + aspirin capsules; PT, prothrombin time.
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Methemoglobin
Mean methemoglobin (metHb) values showed no signif-
icant changes when placebo inhalation was given (HPP,
PPA) but in the PNP and HNP groups, the mean per-
centage increased to maximum values at +30 min
(0.95% and 1.05%, respectively) and returned to baseline
after 2 h (Figure 7). All metHb levels were within nor-
mal limits except for slight increases in some subjects.
Only two subjects experienced Hb levels over 1.5%; one
during all four combination post-dose measurements
(maxima of 1.9% at 30 min post-PPA, 1.6% at 1 h post-
HPP, 2.0% at 30 min post-HNP and 2.4% at 1 h post-
PNP), with the second patient at 30 min post-HNP dose
(1.6%).
Discussion
This investigation of the effects of inhaled NO in
healthy male volunteers found no significant additive
effect on hemostasis, as measured by aPTT and bleeding
time, when administered in combination with a standar-
dized dose of heparin. Analysis of the primary end point
of ACT revealed that the ratio of the AUCs of the
groups that received HPP to those that received HNP
indicated that the treatments were equivalent with
regard to this parameter. Consequently, the addition of
NO did not alter the effect of heparin on ACT. Bleeding
time, PT, aPTT and platelet aggregation were investi-
gated to further address the effects of inhaled NO on
hemostasis. PT and aPTT were prolonged only in those
groups receiving heparin; only groups receiving aspirin
demonstrated prolonged bleeding times or inhibition of
platelet aggregation. As a result, following investigation
Figure 3 Heparin assay data/anti-Xa activity before and at
various time points after treatment with inhaled nitric oxide or
placebo gas. Data points represent mean. HNP, heparin injection +
nitric oxide inhalation + placebo capsules; HPP, heparin injection +
placebo inhalation + placebo capsules; PNP, placebo injection +
nitric oxide inhalation + placebo capsules; PPA, placebo injection +
placebo inhalation + aspirin capsules.
Figure 4 Bleeding time before and at various time points after
treatment with inhaled nitric oxide or placebo gas. Data points
represent mean ± SD. HNP, heparin injection + nitric oxide
inhalation + placebo capsules; HPP, heparin injection + placebo
inhalation + placebo capsules; PNP, placebo injection + nitric oxide
inhalation + placebo capsules; PPA, placebo injection + placebo
inhalation + aspirin capsules.
Figure 5 Platelet aggregation before and at various time
points after treatment with inhaled nitric oxide or placebo gas.
Data points represent mean + SD. ADP, adenosine diphosphate;
HNP, heparin injection + nitric oxide inhalation + placebo capsules;
HPP, heparin injection + placebo inhalation + placebo capsules;
PNP, placebo injection + nitric oxide inhalation + placebo capsules;
PPA, placebo injection + placebo inhalation + aspirin capsules.
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of the effects of inhaled NO on multiple measures of
hemostasis, we found no notable alterations to hemosta-
sis with the use of inhaled NO, including during combi-
nation use with heparin.
In this study, NO inhalation was tolerated well and
resulted in no clinically significant changes from base-
line in safety criteria including metHb levels. The only
AE reported was that of vomiting in one patient while
receiving PNP, deemed possibly related to study medica-
tion. Mean plasma creatinine levels increased over the
first 12 h following study treatment but there was no
sequence, period, or combination effect. This may indi-
cate that the increase was probably a result of study par-
ticipation but not study drug administration. The fasting
period was different for each subject, and the creatinine
results may be a reflection of dehydration or timing of
sampling.
The subject population was that of healthy adult
males; consequently, results may not be generalized to
other patient groups, such as neonates, or in clinical set-
tings such as surgery, where underlying developmental,
pathophysiologic, or clinical conditions may be present.
In addition, caution should be taken in extrapolating
these results to women, although there is no current
clinical evidence to suggest that gender-based differ-
ences exist in terms of NO effects on platelet function.
A study by Gries et al examining the effects of inhaled
NO on platelet function in 18 males and 18 females
found no clear difference in effect between genders [9];
nevertheless, applicability to a female population is
unknown and would be a valuable attribute to future
study in this area.
The inhaled NO dose utilized for this study was 80
ppm, which is substantially greater than the typical
recommended dose of 20 ppm. It should be noted, how-
ever, that in clinical practice, the dose range for inhaled
Figure 6 cGMP levels before and at various time points after
treatment. HNP, heparin injection + nitric oxide inhalation +
placebo capsules; HPP, heparin injection + placebo inhalation +
placebo capsules; PNP, placebo injection + nitric oxide inhalation +
placebo capsules; PPA, placebo injection + placebo inhalation +
aspirin capsules.
Figure 7 Methemoglobin levels before and at various time points after treatment with inhaled nitric oxide or placebo gas. Data points
represent mean + SD. HNP, heparin injection + nitric oxide inhalation + placebo capsules; HPP, heparin injection + placebo inhalation +
placebo capsules; PNP, placebo injection + nitric oxide inhalation + placebo capsules; PPA, placebo injection + placebo inhalation + aspirin
capsules.
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NO is between 1 and 80 ppm As a result, the highest
dose with in this range was chosen for this study to
ensure the maximum potential effect of iNO in terms of
the clinical efficacy and safety end points examined in
this trial.
Exposure time to inhaled NO in this study was rela-
tively short (30 min); this may be a limitation, as most
clinical applications involve more prolonged exposure to
inhaled NO. One can presume, however, that longer
exposure times to inhaled NO would not have contribu-
ted any additional physiologic or safety-based effects in
this study, particularly given the fact that inhaled NO
has a very short half-life (seconds) and reaches steady-
state within 5 to 10 min. In addition, inhaled NO is a
selective pulmonary vasodilator and does not exhibit
systemic effects. While inhaled NO has a duration of
effect on the order of seconds to minutes, the effects of
heparin are longer and dose-dependent–at the heparin
doses administered in this study, duration of effect was
expected to be approximately 60 min.
Standard laboratory tests that were utilized in similar
trials published at the time of study were performed,
including ACT, aPTT, PT, bleeding time, and anti-factor
Xa activity measurements. These measurements are con-
ventional standards in the context of measuring coagula-
tion, but can be limited in terms of the impact of
sampling technique (e.g., tube underfilling, sample con-
tamination) and the use of platelet-poor plasma. Since
the time of this study, new insights regarding coagula-
tion have emerged, highlighting discrepancies between
in vitro-based and in vivo-based processes regarding
coagulation. While the standard tests provide a com-
mon, laboratory-based assessment of coagulation, the
advent of more recent, near-patient/point-of-care
focused testing systems have begun to comprise current
clinical practice. While not preferred approaches in the
clinical trial setting during the time of our study, tests
such as Hemochron-ACT, thromboelastography, platelet
function analysis, and portable INR/PT testing should
be considered when conducting future trials in this area.
One of the key areas of interest when examining the
literature on hemostasis-related effects of inhaled NO is
the heterogeneity of the study designs, patient popula-
tions, controls, and measurements utilized in the various
trials to date. Current medical literature with human
subjects in this regard is limited in scope, with reports
restricted to small patient trials (< 40 patients), case
reports, and specific disease states [7-9,11,13,15,18-22].
Even when examining those trials conducted solely in
healthy volunteers, the clinical conclusions appear con-
tradictory. This study was specifically designed to begin
to provide clarity on specific clinical scenarios by exam-
ining the effect of inhaled NO in a specific and common
controlled, clinical setting.
Results from this study are in accord with two trials in
which aspirin was employed as a control in healthy
volunteers, where inhaled NO inhalation (30 ppm and
80 ppm for 15 to 30 min) was shown to have no influ-
ence on bleeding time or platelet function, while pro-
longed (55 min) exposure to 30 ppm resulted in slight,
but significant (p = 0.04), increases in bleeding time
[11,13]. In a third study, endogenous and inhaled NO
did not influence the function of circulating platelets (i.
e. P-selectin expression, platelet aggregability, and fibri-
nogen binding), most likely due to its rapid inactivation
in the blood. Bleeding time was found to be increased
significantly with NO inhalation; however, it was consid-
ered moderate in nature and of limited clinical relevance
[8].
These results do not reproduce the results of three
other trials in healthy volunteers [7,9,20], which demon-
strated inhibition of platelet aggregation markers (as
described above) with the use of inhaled NO, as well as
prolonged bleeding time in the two trials where mea-
sured [9,20,29].
This study and the subsequent published research sug-
gest that the effect of inhaled NO on bleeding time and
other parameters of hemostasis, at clinically relevant
doses, is modest at best, and of little clinical signifi-
cance. Combined with the clinical literature that fol-
lowed this study, these data may serve as a foundation
for further experiments in a more clinical context (e.g.,
common clinical settings or patients with specific dis-
ease states), as was done in part with the heparin group
in this study.
The wide-ranging experimental evidence surrounding
the effects of inhaled NO on platelet aggregation, bleed-
ing time, and other hemostasis-based parameters has
raised vigilance in the monitoring of related potential
AEs (e.g. hemorrhage) in a setting where inhaled NO is
used. The clinical implications of this study in particular
indicate that use of inhaled NO does not significantly
impact parameters related to hemostasis such as aPTT,
ACT, PT or bleeding time, even when administered in
combination with heparin. This is consistent with the
clinical experience that the use of inhaled NO in the
setting of both adult and pediatric cardiovascular sur-
gery, with or without anticoagulation, is not associated
with clinical bleeding. Those patients are typically maxi-
mally anticoagulated with heparin both during and after
surgery–a scenario similar to that which was tested in
this study. Thus, the results of this pharmacodynamic
study serve to provide additional evidence that inhaled
NO does not predispose to clinical bleeding.
Conclusions
Inhalation of 80 ppm inhaled NO for 30 min was well
tolerated and was not associated with any additive
Goldstein et al. Thrombosis Journal 2012, 10:1
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effects on ACT when administered with heparin. In
addition, other parameters related to hemostasis and
platelet aggregation (e.g. bleeding time, PT, aPTT) were
unaffected by inhaled NO.
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